Full-Time

Senior Scientist

Assay Research

Pattern Bioscience

Pattern Bioscience

51-200 employees

AI-driven rapid bacterial ID and AST

No salary listed

Austin, TX, USA

In Person

Category
Biology & Biotech (2)
,
Required Skills
Biophysics
Machine Learning
Biochemistry
Microbiology
Data Analysis
Requirements
  • Ph.D. in Biochemistry, Biophysics, Bioengineering, or Chemistry with 5+ years of experience in assay research and development
  • Understanding of the rigor of Design Control (ISO 13485/FDA 21 CFR 820) and how to build a design that is manufacturable without compromising performance
  • Experience working with a broad range of pathogens and infectious disease matrices (microbiology expertise)
Responsibilities
  • Architect and execute novel biochemical assays at the bench focusing on single-cell metabolic activity and phenotypic responses within picoliter-scale environments
  • Engineer stable chemistries for raw samples by creating robust sample-prep and assay chemistries designed to maintain high signal-to-noise and assay stability with unrefined, high-interference clinical samples
  • Translate inventions into patentable products by identifying and maturing novel assay concepts and chemistries that are patentable and scalable, collaborating with engineering to move bench-top breakthroughs into production-ready solutions
  • Turn single-cell data into biological insight by applying deep data analysis to characterize single-cell behavior and provide high-quality datasets for machine-learning models for rapid pathogen identification and drug susceptibility testing
Desired Qualifications
  • Hands-on experience with droplet microfluidics, flow cytometry, or other single-cell digitization technologies (Single-Cell/Droplet Expertise)
  • Significant evidence of original contribution to the field through publications or patents

Pattern Bioscience develops rapid clinical diagnostics that identify bacterial infections and determine antibiotic resistance. Its system uses single-cell analysis with AI pattern recognition to deliver definitive ID/AST results in about four hours. The product suite includes diagnostic devices, consumables, service contracts, and software for AI analysis. By speeding and improving accuracy, Pattern Bioscience aims to help hospitals reduce inappropriate antibiotic use and combat antibiotic resistance.

Company Size

51-200

Company Stage

Series D

Total Funding

$91.6M

Headquarters

Austin, Texas

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • $43M Series D funding from AMR Action Fund supports FDA 510(k) submission.
  • $40.9M BARDA contract accelerates pneumonia and bacteremia panel development.
  • Over 1,000 samples enrolled in multi-center trial for Q3 regulatory push.

What critics are saying

  • Accelerate Diagnostics' PhenoVue captures market with FDA-cleared 3-hour AST.
  • BioFire's FilmArray dominates ICU syndromic testing, sidelining single-pathogen focus.
  • Clinical trial failure by mid-2026 exhausts Series D runway, halting launch.

What makes Pattern Bioscience unique

  • Digital CultureTM enables culture-free phenotypic ID/AST in four hours.
  • Single-cell analysis captures all resistance mechanisms unlike genotypic tests.
  • Pneumonia ID/AST Panel targets critically ill patients with FDA Breakthrough Designation.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Pattern Bioscience who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Unlimited Paid Time Off

Paid Holidays

401(k) Company Match

401(k) Retirement Plan

Health Savings Account/Flexible Spending Account

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

2%

2 year growth

-1%
Legal Desire
Nov 19th, 2025
Pattern Bioscience Raises $43M Series D

Pattern Bioscience has raised $43 million in Series D funding, led by AMR Action Fund, Illumina Ventures, and Omnimed Capital. The funds will support a US multi-center clinical trial and regulatory submission for their Pneumonia ID/AST Panel, which has FDA Breakthrough Device Designation and is backed by a BARDA contract worth up to $40.9 million. Latham & Watkins LLP represented Pattern Bioscience in the transaction.

VCBay
Apr 29th, 2023
Austin-based Biotech startup Pattern Bioscience raises USD 28.7 million in Series C funding

To quickly develop effective treatments for drug-resistant bacterial infections, Pattern is a leader in the application of single-cell microbiology.

Business Wire
Apr 28th, 2023
Pattern Bioscience Secures $28.7 Million in Series C Financing

Pattern Bioscience secures $28.7 million in Series C financing to accelerate development of first-of-its-kind infectious disease diagnostic platform

FinSMEs
Apr 27th, 2023
Pattern Bioscience Raises $28.7M in Series C Financing

Pattern Bioscience, an Austin, TX-based company which specializes in rapid diagnosis and antibiotic susceptibility testing (AST) for bacterial infections, raised $28.7M in Series C funding.

360Dx
Apr 27th, 2023
Pattern Bioscience Closes $28.7M Series C Financing Round | 360Dx

Including the Series C round, Pattern has now raised $68 million to date, the company said in a statement.